Both in Pharmaceuticals
UroGen Pharma vs Damora Therapeutics
Over the past year URGN returned −32.1% and DMRA returned −18.4%; their daily moves had a correlation of -0.05.
URGN −32.1% DMRA −18.4%Growth of $1, one year, split-adjusted
| Metric | URGN | DMRA |
|---|---|---|
| Price | $28.74 | $22.94 |
| Market cap | $1.40B | $1.42B |
| Today | −16.45% | +3.89% |
| 1 month | −30.6% | +17.3% |
| 6 months | +9.5% | — |
| Year to date | +22.7% | — |
| 1 year | +39.4% | — |
| Revenue growth (YoY) | +199.2% | — |
| Gross margin | 90.9% | — |
| Net margin | −19.8% | — |
| P/E (TTM) | — | — |
| Price / sales | 7.4× | — |
| Net cash | -$85.1M | $540.5M |
| Dividend yield | — | — |
| Volatility (60d) | 54.9% | — |
| Short % of float | 12.3% | 11.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).